Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440877 | PMC |
| http://dx.doi.org/10.4274/tjh.2016.0428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myeloid Sarcoma: Case Series with Unusual Locations.
Int J Hematol Oncol Stem Cell Res
October 2023
Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Myeloid sarcoma (MS) or chloroma is a localized mass composed of blastic cells of granulocytic lineage. It is a subtype of acute myeloid leukemia and usually presents as a complication of acute myeloid leukemia, myeloid dysplastic syndrome, or myeloproliferative disorder. MS occurs in 2.
View Article and Find Full Text PDFIsolated myeloid sarcoma with pericardial and pleural effusions as first manifestation: A case report.
Medicine (Baltimore)
October 2022
Department of Hematology, Zhongshan Boai Hospital Affiliated to Southern Medical University, Zhongshan, Guangdong, China.
Rationale: Myeloid sarcoma (MS) involves the proliferation of extramedullary blasts from 1 or more myeloid lineages, replacing the original tissue structures, and these neoplasias are called granulocytic sarcoma, chloroma, or extramedullary myeloid neoplasms. These tumors develop in lymphoid organs, bones, skin, soft tissues, various mucous membranes, organs, and the central nervous system. MS is rare in non-leukemic patients, while MS patient with effusion as the first manifestation is even rare.
View Article and Find Full Text PDFIsolated myeloid sarcoma of lumbar spine without bone marrow involvement: a rare case report and treatment dilemma.
AME Case Rep
July 2021
Department of Hematology and Oncology, Kern Medical Center-UCLA, Bakersfield, CA, USA.
Granulocytic sarcoma, chloroma, myeloblastoma, or here referred as myeloid sarcoma (MS), is a rare extramedullary tumor composed of immature myeloid cells called myeloblasts. MS is seen most commonly in patients with acute myeloid leukemia and less frequently in chronic myeloid leukemia, myelodysplastic syndrome. In rarer instances, MS has been shown to precede the development of myeloid tumors by acute myeloblastic leukemia (AML).
View Article and Find Full Text PDFGranulocytic and Monocytic Myeloid-Derived Suppressor Cells are Functionally and Prognostically Different in Patients with Chronic Myeloid Leukemia.
Ann Lab Med
September 2021
Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Myeloid-derived suppressor cells (MDSCs) represent phenotypically heterogeneous populations that suppress tumor-specific T-cell responses. MDSCs are produced from myeloid precursors in emergent states and are increased in several hematologic malignancies. We evaluated the differences in the levels and prognostic significance of MDSCs according to the clinical status of chronic myeloid leukemia (CML).
View Article and Find Full Text PDFVariant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup.
Leuk Lymphoma
October 2019
Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center One Medical Center Drive, Lebanon , NH , USA.
Next generation sequencing (NGS) has introduced new types of data, such as variant allele frequencies (VAFs), into the workup of acute myeloid leukemias (AML). There is interest in using NGS to prognosticate disease behavior and monitor residual disease, but the attribution of sequencing data entirely to the leukemic clone may be confounded by VAF contribution from background non-leukemic populations and undetected copy number aberrations. Sixty-eight patients with AML were evaluated by a clinically validated gene sequencing panel at our institution from 2015 to 2018.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!